Liraglutide

Liraglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist structurally derived from human GLP-1 and modified to provide a longer duration of activity than endogenous GLP-1.

The primary research target of Liraglutide is the GLP-1 receptor (GLP-1R), a G protein-coupled receptor involved in multiple metabolic signaling pathways. Liraglutide therefore provides a research tool for investigating GLP-1R activation and downstream cellular signaling mechanisms.

In glucose metabolism research, Liraglutide is studied in connection with glucose-dependent insulin secretion, pancreatic beta-cell biology, glucagon regulation, and glucose homeostasis.

GLP-1 signaling also involves gastrointestinal and central nervous system pathways. Research therefore includes mechanisms associated with gastric emptying, appetite signaling, satiety, energy intake, body-weight regulation, and energy balance.

Liraglutide is additionally relevant to studies involving lipid metabolism, insulin signaling, energy homeostasis, and metabolic regulation across different tissues, and may be compared experimentally with other GLP-1 analogs and incretin-related research molecules.

Certain pharmaceutical products containing Liraglutide are approved prescription medicines for specific medical indications. Research-grade Liraglutide should not be considered equivalent to an approved pharmaceutical product, and such approvals do not establish the safety, efficacy, or clinical use of a research-grade preparation.

寄往美国、加拿大、墨西哥与欧洲，标准运送满 $50 免运费，订单 1 个工作日内发出。

不满意？30 天内可全额退款，即使已经开封。